Medicine & Life Sciences
Fatty Liver
100%
Adverse Outcome Pathways
53%
2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid
49%
Menstrual Hygiene Products
38%
Thyroid Hormone Receptors beta
33%
Skin
31%
In Vitro Techniques
31%
Non-alcoholic Fatty Liver Disease
30%
Liver Diseases
27%
Phospholipases
26%
Stem Cells
25%
Lipids
23%
Protein Domains
21%
Liver
17%
Fatty Acids
16%
Hepatocytes
14%
Esterification
14%
Bariatric Surgery
13%
Hepatic Stellate Cells
13%
Adenosine Triphosphate
11%
benzyl salicylate
11%
Lipid Metabolism
10%
Allergic Contact Dermatitis
10%
Allergens
10%
Risk Assessment
10%
Liver Cirrhosis
9%
Hydrolysis
9%
Organisation for Economic Co-Operation and Development
9%
Triglycerides
8%
Norisoprenoids
8%
Systematic Reviews
7%
2-(3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro(1,2,4)triazine-6-carbonitrile
7%
Weights and Measures
6%
Peroxisome Proliferator-Activated Receptors
6%
cinnamic aldehyde
6%
piperonal
5%
Lipopolysaccharides
5%
Lipogenesis
5%
Drug Development
5%
Chemistry
Leaching
19%
Sensitizing
17%
Lipid
16%
Risk Assessment
15%
Neurotoxicity
13%
Allergen
13%
Developmental
13%
Sensitization
11%
Fatty Acid
10%
Ionone
8%
Metabolic
8%
Salicylate
8%
Pharmacological Metabolism
8%
Application
7%
Drug
7%
Cinnamaldehyde
6%
Peroxisome Proliferator Activated Receptor Agonist
6%
Modification
5%
Peroxisome Proliferator
5%
Piperonal
5%
Irritant
5%
Protein
5%
